BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maglio D, Teng R, Thyrum PT, Nightingale CH, Nicolau DP. Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid. Antimicrob Agents Chemother 2003;47:1771-3. [PMID: 12709358 DOI: 10.1128/AAC.47.5.1771-1773.2003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Schoenenberger-Arnaiz JA, Ahmad-Diaz F, Miralbes-Torner M, Aragones-Eroles A, Cano-Marron M, Palomar-Martinez M. Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients. Eur J Hosp Pharm 2020;27:e30-5. [PMID: 32296502 DOI: 10.1136/ejhpharm-2018-001713] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
2 Dinh PH, Corraza F, Mestdagh K, Kassengera Z, Doyen V, Michel O. Validation of the cantharidin-induced skin blister as an in vivo model of inflammation. Br J Clin Pharmacol 2011;72:912-20. [PMID: 21595743 DOI: 10.1111/j.1365-2125.2011.04020.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
3 Fish DN. Meropenem in the treatment of complicated skin and soft tissue infections. Ther Clin Risk Manag 2006;2:401-15. [PMID: 18360652 DOI: 10.2147/tcrm.2006.2.4.401] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
4 Urbina T, Razazi K, Ourghanlian C, Woerther PL, Chosidow O, Lepeule R, de Prost N. Antibiotics in Necrotizing Soft Tissue Infections. Antibiotics (Basel) 2021;10:1104. [PMID: 34572686 DOI: 10.3390/antibiotics10091104] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Sun HK, Ong CT, Umer A, Harper D, Troy S, Nightingale CH, Nicolau DP. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 2005;49:1629-32. [PMID: 15793157 DOI: 10.1128/AAC.49.4.1629-1632.2005] [Cited by in Crossref: 60] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
6 Sun HK, Duchin K, Nightingale CH, Shaw JP, Seroogy J, Nicolau DP. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother 2006;50:788-90. [PMID: 16436747 DOI: 10.1128/AAC.50.2.788-790.2006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]